Arkolith/Insider Trading/AGIO/Form 4

Goff Brian

Chief Executive Officer, DirectorAGIOS PHARMACEUTICALS, INC. (AGIO) · full profile →Form 4 · filed Apr 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$662K
Net Open-Market Flow
-$662K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2026Option exercise(M)26K—$0190K
Apr 2, 2026Sell(S)12K$34.71$433K178K
Apr 2, 2026Option exercise(M)14K—$0191K
Apr 2, 2026Sell(S)7K$34.71$229K185K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 2, 2026Option exercise(M)26K—$00
Apr 2, 2026Option exercise(M)14K—$041K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001439222-26-000057) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML